NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $578,000 | +5.7% | 31,865 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $547,000 | -13.6% | 31,865 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $633,000 | +19.4% | 31,865 | +2.2% | 0.00% | 0.0% |
| Q4 2020 | $530,000 | +10.9% | 31,180 | +9.3% | 0.00% | 0.0% |
| Q3 2020 | $478,000 | -63.1% | 28,517 | -50.0% | 0.00% | 0.0% |
| Q2 2020 | $1,294,000 | +156.7% | 57,034 | +100.2% | 0.00% | 0.0% |
| Q1 2020 | $504,000 | -16.7% | 28,485 | -0.5% | 0.00% | 0.0% |
| Q4 2019 | $605,000 | -6.3% | 28,625 | -19.2% | 0.00% | 0.0% |
| Q3 2019 | $646,000 | -48.7% | 35,411 | 0.0% | 0.00% | -66.7% |
| Q2 2019 | $1,260,000 | +29.8% | 35,411 | +22.7% | 0.00% | +50.0% |
| Q1 2019 | $971,000 | +32.1% | 28,862 | +29.3% | 0.00% | +100.0% |
| Q4 2018 | $735,000 | -18.9% | 22,320 | +50.0% | 0.00% | 0.0% |
| Q3 2018 | $906,000 | +155.2% | 14,880 | +104.5% | 0.00% | 0.0% |
| Q2 2018 | $355,000 | +105.2% | 7,276 | +346.1% | 0.00% | – |
| Q1 2018 | $173,000 | – | 1,631 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |